Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD raised its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,058,615 shares of the company's stock after purchasing an additional 188,820 shares during the period. Price T Rowe Associates Inc. MD owned 2.13% of Denali Therapeutics worth $62,335,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Denali Therapeutics by 7.6% during the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock worth $244,993,000 after acquiring an additional 843,996 shares during the last quarter. FMR LLC increased its stake in Denali Therapeutics by 2.4% during the 4th quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after purchasing an additional 188,368 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Denali Therapeutics by 8.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock worth $67,573,000 after buying an additional 268,378 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Denali Therapeutics by 19.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock worth $37,805,000 after buying an additional 295,594 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after buying an additional 149,939 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Trading Up 2.4 %

NASDAQ:DNLI traded up $0.38 during midday trading on Friday, reaching $16.44. The company had a trading volume of 1,118,564 shares, compared to its average volume of 1,086,436. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $33.33. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -5.96 and a beta of 1.49. The stock's fifty day simple moving average is $14.51 and its 200-day simple moving average is $20.51.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DNLI shares. Deutsche Bank Aktiengesellschaft assumed coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 target price for the company. Oppenheimer lowered their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. HC Wainwright boosted their price objective on Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a report on Friday, February 28th. JPMorgan Chase & Co. dropped their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a report on Tuesday, January 7th. Finally, Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $37.57.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.